Cogent Biosciences, Inc. (COGT)
NASDAQ:COGT
Want to see COGT full AI Analyst Report?
COGT Stock Chart & Stats
$37.25
-$0.07(-0.91%)
At close: 4:00 PM EST
$37.25
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$5.49 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)1.78M
Market Cap
$5.60B
Enterprise Value$5.97B
Total Cash (Recent Filing)$866.38M
Total Debt (Recent Filing)$238.65M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 11, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.08
Shares Outstanding170,868,010
10 Day Avg. Volume2,470,492
30 Day Avg. Volume1,775,120
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.71K
Enterprise Value/Ebitda-16.49
Forecast
1Y Price Target
$52.75Price Target Upside41.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$10.85M
Bulls Say, Bears Say
Bulls Say
IND-enabling ProgressOngoing IND-enabling studies with an IND submission expected later this year represent a clear structural advancement from discovery toward clinical development. This milestone can materially de-risk the lead programs, enable human dosing, attract partnerships, and create multi-month to multi-quarter value inflection points tied to regulatory progress rather than short-term market moves.
Highly Selective KRAS CandidateA >500x selectivity profile for the KRAS inhibitor suggests a durable competitive advantage: higher target specificity can allow safer higher dosing, reduce off-target toxicity, and improve therapeutic index. If clinical translation holds, this structural differentiation can sustain better efficacy/tolerability versus less selective rivals and support longer-term market positioning.
Sizable Equity CushionHaving roughly $608M of equity relative to $903M in assets provides a meaningful capital cushion for a clinical-stage biotech. This structural balance-sheet strength offers near-term financial flexibility to fund R&D and regulatory activities, reducing immediate insolvency risk and giving management time to advance programs before needing dilutive financing.
Bears Say
No Commercial RevenueThe absence of commercial revenue means the company is wholly dependent on capital markets or partnerships to fund operations. With no product-derived cash inflows, ongoing R&D and regulatory timelines must be financed externally, structurally increasing dilution risk and making long-term sustainability contingent on successful clinical/regulatory milestones.
Heavy, Rising Cash BurnSustained and increasing negative operating and free cash flow (roughly -$285M TTM) is a structural weakness: it shortens runway absent financing, pressures liquidity, and forces strategic choices (slow programs, partner deals, or equity raises). Volatility in free cash flow growth suggests no clear trend to self-sustaining cash generation in coming quarters.
Rising Leverage And Financing RiskThe marked increase in debt relative to prior years raises structural financing risk for a pre-revenue biotech. Higher leverage adds interest and covenant exposure, reduces capital flexibility, and heightens the probability of dilutive equity raises or restrictive financings if cash burn continues, eroding long-term shareholder value absent clear de-risking events.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences, Inc.’s price range in the past 12 months?
Cogent Biosciences, Inc. lowest stock price was $5.49 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences, Inc.’s market cap?
Cogent Biosciences, Inc.’s market cap is $5.60B.
When is Cogent Biosciences, Inc.’s upcoming earnings report date?
Cogent Biosciences, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 68 days.
How were Cogent Biosciences, Inc.’s earnings last quarter?
Cogent Biosciences, Inc. released its earnings results on May 05, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.533 by $0.003.
Is Cogent Biosciences, Inc. overvalued?
According to Wall Street analysts Cogent Biosciences, Inc.’s price is currently Undervalued.
Does Cogent Biosciences, Inc. pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
What is Cogent Biosciences, Inc.’s EPS estimate?
Cogent Biosciences, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Cogent Biosciences, Inc. have?
Cogent Biosciences, Inc. has 170,868,010 shares outstanding.
What happened to Cogent Biosciences, Inc.’s price movement after its last earnings report?
Cogent Biosciences, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.533. Following the earnings report the stock price went up 0.681%.
Which hedge fund is a major shareholder of Cogent Biosciences, Inc.?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.75 (41.61% Upside)
$52.75 (41.61% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $242.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
483.95%
12-Months-Change
Fundamentals
Return on Equity
-83.29%
Trailing 12-Months
Asset Growth
218.19%
Trailing 12-Months
Company Description
Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$52.75
▲(41.61% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
4.03% Insiders
30.32% Mutual Funds
44.21% Other Institutional Investors
6.31% Public Companies and
Individual Investors